Treosulfan
Information
- Drug Name
- Treosulfan
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| MITF amplification does not predict chemosensitivi... | MITF | MITF AMP | Resitance or Non-Reponse | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00491634 | Completed | Phase 2 | Treosulfan-based Conditioning for Transplantation in AML/MDS | June 2007 | June 2014 |
| NCT00822393 | Completed | Phase 3 | Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC) | November 24, 2008 | January 25, 2018 |
| NCT02048800 | Completed | Treosulfan Pharmacokinetics in Children Undergoing Allogeneic HSCT | March 2014 | July 31, 2017 | |
| NCT02333058 | Completed | Phase 2 | Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies | November 21, 2014 | September 30, 2019 |
| NCT02349906 | Completed | Phase 2 | Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases | April 2015 | April 2023 |
| NCT00796068 | Completed | Phase 2 | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant | February 24, 2009 | December 14, 2021 |
| NCT03961919 | Completed | Phase 2 | Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant | February 10, 2009 | December 31, 2021 |
| NCT00860574 | Completed | Phase 2 | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia | February 2009 | |
| NCT00919503 | Completed | Phase 2 | Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders | July 31, 2009 | June 10, 2020 |
| NCT00987636 | Completed | Phase 3 | Study in Localized and Disseminated Ewing Sarcoma | October 1, 2009 | March 31, 2019 |
| NCT01062490 | Completed | Phase 2 | Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS) | November 2004 | October 2009 |
| NCT01063647 | Completed | Phase 1/Phase 2 | Dose-range Finding Treosulfan-based Conditioning | November 2001 | June 2006 |
| NCT01063660 | Completed | Phase 2 | Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML) | March 2004 | July 2007 |
| NCT00170690 | Completed | Phase 3 | Preference Study With Elderly Patients Recurrent Ovarian Cancer | August 2004 | April 2012 |
| NCT01772953 | Completed | Phase 2 | Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT | September 2013 | August 2015 |
| NCT00253513 | Completed | Phase 1/Phase 2 | Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | June 2005 | October 2009 |
| NCT03980769 | Recruiting | Phase 2 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders | May 5, 2021 | July 1, 2027 |
| NCT04965597 | Recruiting | Phase 2 | Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) | April 19, 2022 | December 2026 |
| NCT04994808 | Recruiting | Phase 2 | Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia | August 11, 2023 | April 3, 2027 |
| NCT05534620 | Recruiting | Phase 1 | Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics | February 1, 2024 | December 2025 |
| NCT05636787 | Recruiting | Phase 2 | Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients | June 6, 2023 | April 2028 |
| NCT06198842 | Recruiting | Phase 2 | Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage Syndrome | November 22, 2023 | January 31, 2029 |
| NCT01949129 | Recruiting | Phase 2/Phase 3 | Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia | April 2013 | April 2030 |
| NCT04195633 | Recruiting | Phase 2 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | January 25, 2021 | December 31, 2026 |
| NCT01810926 | Unknown status | Phase 2 | T&B Depletion Non Malignant | September 2011 | October 2016 |
| NCT00168870 | Unknown status | Phase 2 | Study of Metastatic Ocular Melanoma | February 2003 | |
| NCT01079013 | Unknown status | Phase 2 | Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies | March 2010 | April 2018 |
| NCT00129155 | Unknown status | Phase 2 | MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies | February 2005 | |
| NCT01894477 | Unknown status | Phase 2 | Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | November 2013 | June 2022 |
| NCT02852083 | Unknown status | Phase 2 | A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC | January 2016 | July 2020 |
| NCT04400045 | Unknown status | Phase 2 | Low Dose Treosulfan Based Conditioning Regimen in HSCT for Nijmegen Breakage Syndrome | May 22, 2020 | May 2023 |